New Perspectives Regarding Anaplastic Thyroid Carcinoma Approach Improvement

Author(s): Ana Sofia Figueiredo, Patricia Andrea-Ferreira*

Journal Name: Endocrine, Metabolic & Immune Disorders - Drug Targets
Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders

Volume 18 , Issue 6 , 2018

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background and Objective: Anaplastic thyroid carcinoma is rare, but represents the deadliest type of thyroid cancer that is characterised by a rapid course. Diagnosis is usually made at a late stage, when more than half of the patients have distant metastasis. Our main purpose is to review the current information on anaplastic thyroid aetiology and risk factors that might contribute to an earlier diagnosis as well as to give new perspectives regarding the most recent treatment options and future directions.

Results: The treatment options are mainly palliative and lack efficacy. In particular, the multikinase inhibitors, BRAF inhibitors and other directed agents aim to stabilize the tumour growth and might enable a radical surgery with curative intent.

Conclusion: With the mutational landscape investigation and the discovery of new targets, new directed treatments are being tried. Considering the current tendency to be more conservative regarding the multinodular goiter approach and some differentiated thyroid carcinomas treatment, it is vital to understand that it might evolve to anaplastic cancers.

Keywords: Anaplastic thyroid carcinoma, aetiology, prognostic factors, risk factors, treatment, new approaches.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 10 June, 2018
Page: [555 - 564]
Pages: 10
DOI: 10.2174/1871530318666180611095622
Price: $65

Article Metrics

PDF: 31